A Phase 2 interventional study of lasofoxifene and Placebo in Osteoporosis, sponsored by Ligand Pharmaceuticals. Completed at 17 sites in 3 countries. Open to female participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-08-10.
Sponsored by Ligand Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Osteoporosis with a site in Japan — 7 open to participants now, 7 under way, none of them phase 3. Osteoporosis · Japan.
Among the 42 studies in Osteoporosis with a site in Japan, this one is the 9th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2004, is one of 9 in phase 2, and was the 2nd registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →7 of the 42 studies in Osteoporosis with a site in Japan are open now. Recruiting first, the newest first:
AO Foundation, AO Spine · Sites in Japan, United States, Argentina and 11 more countries
Ages 50+
AgNovos Healthcare, LLC · Sites in Japan, Austria, Belgium and 8 more countries
Ages 65–91 · Women only
Shinshu University · Sites in Japan
Ages 20–120
Shinshu University · Sites in Japan
Ages 20–120
Shinshu University · Sites in Japan
Ages 20+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 40 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 10 · Phase 4 5
First in 1996; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 497 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 170 across the 29 interventional studies, 540 across the 12 observational. Of the 24 that completed or were terminated, 11 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ligand Pharmaceuticals, one of the names counted as Ligand Pharmaceuticals Incorporated. Under that name alone:
Ligand Pharmaceuticals is the lead sponsor of 21 studies on the registry; none are open to participants now.
Ligand Pharmaceuticals Incorporated has 4 studies filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Osteoporosis with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04796350AgNovos Healthcare, LLCRESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies in Osteoporosis with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To establish the optimal dose of lasofoxifene that is fully effective in increasing the BMD in postmenopausal Asian women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.05 mg
Drug: lasofoxifene
0.25 mg
Drug: Lasofoxifene
0.5 mg
Drug: Lasofoxifene
0 mg
Drug: Placebo
0.05 mg tablets
0 mg
0.25 mg tablets
0.5 mg tablets
Effects of lasofoxifene compared to placebo on Bone Mineral Density (BMD) changes at the spine and hip after 1 year of treatment
Percent change from baseline in lumbar spine BMD at Month 12
Time frame: 12 months
Hip BMD, bone markers, lipids and new radiographic vertebral fractures at 1 year
Percent change from baseline in lumbar spine BMD at Month 6, percent change in baseline in hip BMD at Month 6 and Month 12, percent change from baseline in bone metabolism markers at Month 6 and Month 12, percent change from baseline in serum lipids, total cholesterol, high-density lipoprotein cholesterol, triglycerides, lipoprotein (a), apoliporpotein-A1, apolipoprotein-B at Month 6 and Month 12 and incidence of new vertebral fractures at Month 12
Time frame: Month 6 and Month 12
The record gives a start of Jun 2004, a primary completion of Mar 2006 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lasofoxifene